Please assess the completion status of the following clinical trial:

Trial Title: Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 12 months of treatment with infliximab, etanercept and adalimumab.~2. Diagnosis of spondylarthritis according to the European Spondyloarthritis Study Group (ESSG) criteria or modified New York Criteria~3. No clinical active disease, defined as a BASDAI score \< 4.~4. Among other issues: Age \>18 years; written informed consent, adequate birth control; no contraindications for anti-TNF-alpha-therapy~Exclusion Criteria:~1. Treatment with disease modifying anti-rheumatic drugs within 4 weeks before screening~2. Oral, intraarticular, intramuscular or intravenous glucocorticoid within 4 weeks before screening~3. Pregnancy or lactation~4. HIV, hepatitis B or C, tuberculosis, other infections~5. Malignancies~6. Other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological ore cerebral disease (including demyelinating disease)~7. Contraindications to anti-TNF-alpha-therapy~8. Contraindications to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).